State Street’s Allarity Therapeutics ALLR Stock Holding History

State Street’s Portfolio ALLR Stock Details ALLR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$178K	Hold	137,600	–	–	﹤0.01%	3934
2026 Q1	$150K	Hold	137,600	–	–	﹤0.01%	3957
2025 Q4	$149K	Hold	137,600	–	–	﹤0.01%	3968
2025 Q3	$217K	Buy	+137,600	New	+$173K	﹤0.01%	3891
2023 Q1	–	Hold	0	–	-$3.81K	–	4787
2022 Q4	–	Hold	0	–	–	–	4840
2022 Q3	–	Hold	0	–	–	–	4866
2022 Q2	–	Hold	0	–	–	–	4889

Other funds holding ALLR

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street's ALLR Position: Q2 2026 in Review

State Street held its Allarity Therapeutics (ALLR) position steady in Q2 2026 at 137,600 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #3934.

State Street first reported a position in ALLR in Q3 2025 and has held it in 4 quarters since. The position peaked at $217K in Q3 2025. 20 funds tracked by Wall St. Rank hold ALLR as of Q2 2026.

State Street held 137,600 shares of Allarity Therapeutics worth $178K as of Q2 2026.
State Street left its Allarity Therapeutics share count unchanged in Q2 2026.
Allarity Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3934 holding.
State Street first reported a position in Allarity Therapeutics in Q3 2025 and has held it in 4 quarters since.
State Street's Allarity Therapeutics position peaked at $217K in Q3 2025.
20 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.